A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 274 sites in 18 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 3rd largest by enrollment, is one of 4 that started in 2010, is one of 22 in phase 3, and was the 4th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 4 started in 2010.
This study's enrollment of 16,165 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2010, is one of 25 in phase 3, and was the 8th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 50 years.
Two studies [ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)] are being conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. The protocol posting of study ZOSTER-022 also deals with the outcome measures related to the pooled analysis.
This protocol summary has been updated following Protocol Amendment 4 changes to study objectives and endpoints and the analyses of the objectives in 2 steps.
Step 1 will include analyses of the following objectives of ZOSTER-006 (NCT01165177): all HZ VE objectives and all reactogenicity/safety and immunogenicity objectives. At step 2, all objectives of study ZOSTER-006 (NCT01165177) will be analyzed. Objectives already analyzed at step 1 will be re-analyzed (confirmatory descriptive in case of inferential analysis at step 1 or descriptive analysis otherwise). At step 2, pooled analyses of studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) are planned; overall PHN VE in subjects ≥ 70 YOA, and other pre-specified endpoints will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or .
OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate for 30 days prior to vaccination, and has a negative urine pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
Biological: Herpes Zoster Vaccine GSK1437173A
Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
Biological: Placebo
Intramuscular injection
Intramuscular injection
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases
Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN)
The incidence of PHN was calculated using the modified total vaccinated chort.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain
Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Confirmed HZ Episode Related Mortality
The analysis focused on the number of subjects who died due to HZ
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With HZ Related Complications
The analysis focused on the incidence of HZ complications in subjects with confirmed HZ
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Confirmed HZ Episode Related Hospitalizations
The analysis focused on confirmed HZ episode related hospitalizations.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ
The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ
The analysis focused on subjects taking pain medication due to HZ
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Days With Severe 'Worst' HZ-associated Pain.
Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations
The analysis focused on confirmed HZ episode related hospitalizations and deaths.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With HZ Related Complications, by Complication Type
Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Distribution of Pain Medication Associated With HZ
The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Days of Pain Medication Associated With HZ
The analysis was performed on subjects with a confirmed HZ episode
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.
Time frame: During the 7-day (Days 0-6) post-vaccination period
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within the 7-day (Days 0-6) post-vaccination period
Number of Subjects With Any and Grade 3 Symptoms (Solicited and Unsolicited)
Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated
Time frame: Within the 7-day (Days 0-6) post-vaccination period
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With AEs With Any and Related Medically Attended Visit
Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.
Time frame: From Month 0 to Month 8 post-vaccination
Number of Subjects With Unsolicited Adverse Events (AEs)
Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within 30 days (Days 0 - 29) after each vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Within the 30-day (Days 0-29) post-vaccination period, up to Month 14 and up to study end (3 to 5 year period following Day 0)
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine
The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Fatal SAEs
Number of subjects with fatal SAEs during the entire study period were tabulated
Time frame: During the entire study period (3 to 5 years following day 0)
| Milestone | GSK1437173A Group | Placebo Group |
|---|---|---|
| Started | 7695 | 7710 |
| Completed | 6773 | 6808 |
| Not completed | 922 | 902 |
| Withdrew: Serious adverse event | 227 | 235 |
| Withdrew: Withdrawal by subject | 368 | 354 |
| Withdrew: Protocol violation | 19 | 21 |
| Withdrew: Non-serious adverse event | 30 | 18 |
| Withdrew: Other unspecified reasons | 47 | 35 |
| Withdrew: Suspected hz episode | 0 | 2 |
| Withdrew: Lost to follow-up | 183 | 194 |
| Withdrew: Migrated/ moved from study area | 48 | 43 |
Confirmed HZ cases during the study were assessed in the Modified Total Vaccinated Cohort (mTVc)
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | 3 | 2 | 1 | 6 | 87 | 75 | 48 | 210 |
The incidence of PHN was calculated using the modified total vaccinated chort.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any Episodes of Post-Herpetic Neuralgia (PHN) | 0 | 0 | 0 | 0 | 8 | 2 | 8 | 18 |
Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) questionnaire. The outcome assessed the duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the ZBPI in subjects with confirmed HZ. This analysis involved any subject reporting clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With a Reduction of Duration of Severe 'Worst' HZ-associated Pain | 4 | 1 | 2 | 7 | 91 | 74 | 56 | 221 |
The analysis focused on the number of subjects who died due to HZ
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Confirmed HZ Episode Related Mortality | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The analysis focused on the incidence of HZ complications in subjects with confirmed HZ
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With HZ Related Complications | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 6 |
The analysis focused on confirmed HZ episode related hospitalizations.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Confirmed HZ Episode Related Hospitalizations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The analysis focused on patients who experienced a reduction in duration of pain medication administered for HZ in subjects with confirmed HZ.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With a Confirmed HZ Episode Having a Reduction of Duration of Pain Medication Associated With HZ | 3 | 2 | 1 | 6 | 82 | 63 | 45 | 190 |
The analysis focused on subjects taking pain medication due to HZ
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With a Confirmed HZ Episode Taking Pain Medication Associated With HZ | 3 | 2 | 1 | 6 | 82 | 63 | 45 | 190 |
Severe 'worst' pain was defined as HZ-associated pain rated as 3 or above on the 'worst pain' ZBPI questionnaire. This Outcome Measure was only assessed participants with confirmed HZ. This analysis involved any subject reporting ZBPI clinically significant pain (i.e. pain with a score of 3 or more on a 0-10 point scale) at any time during the study.
| Days | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Days With Severe 'Worst' HZ-associated Pain. | 12.0 ± 11.8 | 78.0 ± 0.0 | 9.0 ± 4.2 | 20.6 ± 26.8 | 28.7 ± 48.4 | 21.6 ± 29.3 | 44.0 ± 74.4 | 30.2 ± 51.9 |
The analysis focused on confirmed HZ episode related hospitalizations and deaths.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Mortality | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hospitalization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mortality or hospitalization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Complication types included HZ vasculitis, Disseminated Disease, Ophtalmic Disease, Neurologic Disease, Visceral Disease and Stroke. This Outcome Measure was only assessed participants with confirmed HZ.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| At least one complication | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 6 |
| HZ vasculitis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Disseminated Disease | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Ophtalmic Disease | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Neurologic Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Visceral Disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stroke | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The distribution of pain medication included 1 to 3 or more separate medications. This Outcome Measure was only assessed on participants with confirmed HZ.
| Participants | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| At least one pain medication | 3 | 2 | 1 | 6 | 82 | 63 | 45 | 190 |
| 1 pain medication only | 1 | 1 | 0 | 2 | 30 | 23 | 14 | 67 |
| 2 pain medications only | 1 | 1 | 0 | 2 | 26 | 19 | 9 | 54 |
| 3 pain medications or more | 1 | 0 | 1 | 2 | 26 | 21 | 22 | 69 |
The analysis was performed on subjects with a confirmed HZ episode
| Days | GSK1437173A 50-59 YOA Group | GSK1437173A 60-69 YOA Group | GSK1437173A Over 70 YOA Group | GSK1437173A Overall Ages Group | Placebo 50-59 YOA Group | Placebo 60-69 YOA Group | Placebo Over 70 YOA Group | Placebo Overall Ages Group |
|---|---|---|---|---|---|---|---|---|
| Number of Days of Pain Medication Associated With HZ | 17.3 ± 14.5 | 20.5 ± 16.3 | 63.0 ± 0.0 | 26.0 ± 21.6 | 49.2 ± 121.5 | 74.3 ± 166.3 | 127.7 ± 266.9 | 76.1 ± 181.5 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 3120 | 352 |
| Grade 3 Pain, Dose 1 | 159 | 6 |
| Any Redness, Dose 1 | 1225 | 40 |
| Grade 3 Redness, Dose 1 | 82 | 0 |
| Any Swelling, Dose 1 | 810 | 31 |
| Grade 3 Swelling, Dose 1 | 28 | 0 |
| Any Pain, Dose 2 | 2807 | 258 |
| Grade 3 Pain, Dose 2 | 185 | 10 |
| Any Redness, Dose 2 | 1151 | 24 |
| Grade 3 Redness, Dose 2 | 56 | 0 |
| Any Swelling, Dose 2 | 762 | 17 |
| Grade 3 Swelling, Dose 2 | 18 | 0 |
| Any Pain, Overall | 3463 | 490 |
| Grade 3 Pain, Overall | 293 | 16 |
| Any Redness, Overall | 1665 | 59 |
| Grade 3 Redness, Overall | 121 | 0 |
| Any Swelling, Overall | 1153 | 46 |
| Grade 3 Swelling, Overall | 43 | 0 |
Assessed solicited general symptoms were fatigue, GI (gastrointestinal) symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any Fatigue, Dose 1 | 1395 | 531 |
| Grade 3 Fatigue, Dose 1 | 109 | 29 |
| Related fatigue, Dose 1 | 1153 | 355 |
| Any GI symptoms, Dose 1 | 465 | 263 |
| Grade 3 GI symptoms, Dose 1 | 30 | 12 |
| Related GI symptoms, Dose 1 | 317 | 141 |
| Any Headache, Dose 1 | 1112 | 511 |
| Grade 3 Headache, Dose 1 | 67 | 20 |
| Related Headache, Dose 1 | 891 | 341 |
| Any Myalgia, Dose 1 | 1446 | 377 |
| Grade 3 Myalgia, Dose 1 | 104 | 21 |
| Related Myalgia, Dose 1 | 1231 | 265 |
| Any Shivering, Dose 1 | 632 | 166 |
| Grade 3 Shivering, Dose 1 | 69 | 3 |
| Related Shivering, Dose 1 | 539 | 104 |
| Any Temperature, Dose 1 | 500 | 65 |
| Grade 3 Temperature, Dose 1 | 7 | 1 |
| Related Temperature, Dose 1 | 420 | 38 |
| Any Fatigue, Dose 2 | 1456 | 379 |
| Grade 3 Fatigue, Dose 2 | 157 | 18 |
| Related fatigue, Dose 2 | 1270 | 279 |
| Any GI symptoms, Dose 2 | 495 | 183 |
| Grade 3 GI symptoms, Dose 2 | 33 | 14 |
| Related GI symptoms, Dose 2 | 392 | 91 |
| Any Headache, Dose 2 | 1249 | 340 |
| Grade 3 Headache, Dose 2 | 105 | 13 |
| Related Headache, Dose 2 | 1107 | 219 |
| Any Myalgia, Dose 2 | 1474 | 274 |
| Grade 3 Myalgia, Dose 2 | 160 | 13 |
| Related Myalgia, Dose 2 | 1314 | 197 |
| Any Shivering, Dose 2 | 947 | 128 |
| Grade 3 Shivering, Dose 2 | 139 | 9 |
| Related Shivering, Dose 2 | 838 | 88 |
| Any Temperature, Dose 2 | 645 | 72 |
| Grade 3 Temperature, Dose 2 | 8 | 5 |
| Related Temperature, Dose 2 | 571 | 40 |
| Any Fatigue, Overall | 2006 | 728 |
| Grade 3 Fatigue, Overall | 241 | 46 |
| Related fatigue, Overall | 1724 | 522 |
| Any GI symptoms, Overall | 787 | 386 |
| Grade 3 GI symptoms, Overall | 61 | 25 |
| Related GI symptoms, Overall | 591 | 206 |
| Any Headache, Overall | 1714 | 700 |
| Grade 3 Headache, Overall | 157 | 30 |
| Related Headache, Overall | 1470 | 469 |
| Any Myalgia, Overall | 2023 | 529 |
| Grade 3 Myalgia, Overall | 236 | 31 |
| Related Myalgia, Overall | 1791 | 390 |
| Any Shivering, Overall | 1232 | 259 |
| Grade 3 Shivering, Overall | 192 | 11 |
| Related Shivering, Overall | 1082 | 177 |
| Any Temperature, Overall | 940 | 132 |
| Grade 3 Temperature, Overall | 14 | 6 |
| Related Temperature, Overall | 813 | 78 |
Number of subjects with any and grade 3 solicited and unsolicited symptoms were tabulated
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any solicited or unsolicited symptoms | 3766 | 1691 |
| Grade 3 solicited or unsolicited symptoms | 759 | 145 |
Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all subjects
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any pIMDs | 87 | 105 |
| Related pIMDs | 8 | 12 |
Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits in all subjects.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any medically attended visits | 2952 | 3072 |
| Related medically attended visits | 142 | 60 |
Occurrence, intensity and relationship to vaccination of unsolicited AEs, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any unsolicited AEs | 3534 | 2426 |
| Grade 3 unsolicited AEs | 609 | 298 |
| Related unsolicited AEs | 2199 | 439 |
Occurrence and relationship to vaccination of all SAEs in all subjects. Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Any SAEs (up to Day 30) | 88 | 97 |
| Related SAEs (up to Day 30) | 1 | 3 |
| Any SAEs (up to Month 14) | 594 | 590 |
| Related SAEs (up to Month 14) | 3 | 6 |
| Any SAEs (up to study end) | 727 | 731 |
| Related SAEs (up to study end) | 3 | 7 |
The number of subjects with SAEs related to study participation or to a concurrent GSK medication/vaccine were tabulated
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine | 43 | 25 |
Number of subjects with fatal SAEs during the entire study period were tabulated
| Participants | GSK1437173A Group | Placebo Group |
|---|---|---|
| Number of Subjects With Fatal SAEs | 208 | 221 |
Collected over Solicited symptoms: within 7 days post-vaccination Unsolicited AEs: within 30 days post vaccination SAEs: during the entire study period (3 to 5 year period following Day 0). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 11/7,695 (0.1%) | 727/7,695 (9.4%) | 5,586/7,695 (72.6%) |
| Placebo Group | 15/7,710 (0.2%) | 731/7,710 (9.5%) | 1,893/7,710 (24.6%) |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PneumoniaInfections and infestations | 40/7695 | 26/7710 |
| Myocardial infarctionCardiac disorders | 28/7695 | 27/7710 |
| Cardiac failureCardiac disorders | 20/7695 | 24/7710 |
| Atrial fibrillationCardiac disorders | 19/7695 | 6/7710 |
| Cerebrovascular accidentNervous system disorders | 19/7695 | 12/7710 |
| Acute myocardial infarctionCardiac disorders | 8/7695 | 19/7710 |
| Coronary artery diseaseCardiac disorders | 11/7695 | 17/7710 |
| DeathGeneral disorders | 11/7695 | 15/7710 |
| Cardiac failure congestiveCardiac disorders | 14/7695 | 10/7710 |
| SepsisInfections and infestations | 7/7695 | 13/7710 |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PainGeneral disorders | 3575/7695 | 505/7710 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2277/7695 | 571/7710 |
| FatigueGeneral disorders | 2211/7695 | 770/7710 |
| HeadacheNervous system disorders | 2167/7695 | 929/7710 |
| ErythemaSkin and subcutaneous tissue disorders | 1690/7695 | 69/7710 |
| PyrexiaGeneral disorders | 1498/7695 | 168/7710 |
| ChillsGeneral disorders | 1464/7695 | 276/7710 |
| Injection site painGeneral disorders | 1390/7695 | 104/7710 |
| SwellingGeneral disorders | 1154/7695 | 46/7710 |
| Gastrointestinal disorderGastrointestinal disorders | 792/7695 | 389/7710 |
| Age, Continuous(Years) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 62.4 ± 9.0 | 62.3 ± 9.0 | 62.35 ± 9.0 |
| Age, Customized(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| 50 - 59 YOA | 3644 | 3642 | 7286 |
| 60 - 69 YOA | 2243 | 2245 | 4488 |
| >= 70 YOA | 1808 | 1823 | 3631 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Placebo Group | Total |
|---|---|---|---|
| Female | 4709 | 4711 | 9420 |
| Male | 2986 | 2999 | 5985 |
Showing the first 100 of 274 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2010 to primary completion in May 2014, 45 months.
Results were first posted in May 2017, 2 years 11 months after primary completion. A results delay was requested in Aug 2013.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 45 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix